Elecsys pTau181 is the first In Vitro Diagnostic Regulation (IVDR) certified test to rule out Alzheimer’s associated amyloid pathology.The minimally invasive, blood-based test can serve as a rule out for Alzheimer’s pathology, reducing the need for confirmatory testing with a negative result.Data from clinical study supports use in primary care for people with varying signs of cognitive decline. Basel, 23 July 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today it has received CE Mark for its Elecsys® ...

The Management Board of EfTEN Capital AS approved the updated version of the terms and conditions of EfTEN United Property Fund (hereinafter referred to as the Fund) by its decision of 19.06.2025. The Financial Supervision Authority approved the amendments to the Fund's terms and conditions on 20.07.2025. As a result of the amendment to the Fund's terms and conditions, the wording of the Fund's investment restrictions was clarified in clause 3.11 of the terms and conditions. As a result of the clarification ...

VIENNA, Austria – July 23, 2025 – Today, BAWAG Group released its results for the second quarter 2025, reporting a net profit of € 210 million, earnings per share of € 2.65, and a RoTCE of 27.6%. Pre-provision profits were at € 345 million and the cost-income ratio at 37.5%. This resulted in a net profit of € 411 million, earnings per share of € 5.19, and a RoTCE of 26.7% for the first half of 2025. The CET1 ratio was at 13.5% after deducting the share buyback of € 175 million and the dividend accrual of € ...

Global ingredient supplier Corbion has once again demonstrated its strong commitment to sustainability, earning high marks in climate, water, and supplier engagement in CDP’s Disclosure Cycle 2024. Corbion, the sustainable ingredients company dedicated to preserving what matters, earned scores of A- in Climate, B in Water, and A- in Supplier Engagement, as determined by CDP, a global non-profit that runs the world’s only independent environmental disclosure system. Results are based on data reported by Corb ...

Approval based on INAVO120 data showing the Itovebi™ (inavolisib)-based regimen more than doubled progression-free survival compared with palbociclib and fulvestrant alone1 Up to 40% of ER-positive breast cancers have a PIK3CA mutation and are associated with poor prognosis; this approval helps address an urgent unmet need2-4Itovebi is the first PI3K-targeted therapy to significantly extend survival, reinforcing the need for biomarker testing at diagnosis5 Basel, 23 July 2025 - Roche (SIX: RO, ROG; OTCQX: R ...

PRESS RELEASEJuly 23, 2025 RENAULT GROUP BRANDS STAY THE COURSE IN A CHALLENGING ENVIRONMENT Renault Group recorded an increase in its overall sales in the first half of 2025 (+1.3% vs 2024), reaching 1,169,773 vehicles sold.Internationally1, the Renault brand grew by 16.3% with the commercial success of the first models of the International Game Plan.In Europe2, in a passenger car (PC) market down by 1.0%, the Group grew by 5.4% and reached 708,106 registered vehicles. Sandero and Clio are the two top-sell ...

HIAB CORPORATION, HALF-YEAR FINANCIAL REPORT JANUARY–JUNE 2025, 23 JULY 2025 AT 8:00 AM (EEST) Hiab's half-year financial report January–June 2025: Strong performance in the first half Key takeaways from the quarter Orders received in Q2 increased from the comparison period to EUR 377 (348) millionComparable operating profit margin in Q2 improved to 15.0 (14.5) percent due to strong execution on commercial and supply chain actionsElevated market uncertainty due to the increased trade tensions continuedOutlo ...

Core Viewpoint - Equinor is set to commence the third tranche of its share buy-back program for 2025, amounting to up to USD 1,265 million, with a specific focus on purchasing shares worth up to USD 417.5 million in the market [1][2]. Group 1: Share Buy-Back Program Details - The total share buy-back program for 2025 is up to USD 5 billion, which includes shares to be redeemed from the Norwegian State, and is structured into tranches [2]. - The third tranche will be executed under a non-discretionary agreement with a third party, allowing independent trading decisions [2]. - The maximum number of shares that can be purchased in the market is 84 million, with 67,622,812 shares remaining available at the start of the third tranche [5]. Group 2: Cancellation and Redemption Process - All shares purchased in the third tranche will be cancelled through a capital reduction at the annual general meeting in May 2026 [4]. - The Norwegian State will vote for the cancellation of shares purchased in the market and redeem a proportionate number of its shares to maintain a 67% ownership stake [6][8]. Group 3: Regulatory Compliance - Share purchases will be conducted on the Oslo Stock Exchange and possibly other trading venues within the EEA, adhering to applicable safe harbour conditions and regulations [7]. - The board of directors will propose the cancellation of shares purchased in the third tranche at the annual general meeting in May 2026 [8].

Core Points - Equinor (OSE: EQNR, NYSE: EQNR) has announced a cash dividend of 0.37 USD for the second quarter of 2025 [1] - The last day to include rights for the dividend is 12 November 2025 [1] - The ex-date for Oslo Børs is 13 November 2025, and for the New York Stock Exchange, it is 14 November 2025 [1] - The record date for the dividend is set for 14 November 2025 [1] - The payment date for the dividend is scheduled for 26 November 2025 [1] - The approval date for the dividend was 22 July 2025 [1] - The cash dividend per share in NOK will be communicated on 20 November 2025 [1] Regulatory Compliance - The information is published in accordance with the Euronext Oslo Børs Continuing Obligations [2] - It is subject to the disclosure requirements pursuant to Section 5-12 in the Norwegian Securities Trading Act [2]

Financial Performance - Equinor reported an adjusted operating income of USD 6.53 billion and an adjusted net income of USD 1.67 billion for Q2 2025, leading to adjusted earnings per share of USD 0.64 [1][8] - The net operating income decreased to USD 5.72 billion from USD 7.66 billion in the same quarter last year, impacted by an impairment of USD 955 million due to regulatory changes [9] - Cash flows from operating activities before taxes and working capital items amounted to USD 9.17 billion for the quarter [10] Production and Operational Highlights - Total equity production reached 2,096 mboe per day, a 2% increase from 2,048 mboe in Q2 2024 [4] - The US onshore assets contributed to a 28% increase in oil and gas production compared to the same period last year [5] - The Johan Castberg field reached production plateau shortly after starting operations, contributing to strong operational performance [14] Strategic Developments - Equinor is progressing its renewable energy portfolio, with financial closure on the Baltyk 2 and 3 offshore wind projects in Poland, totaling EUR 6 billion [16] - The company announced the divestment of the Peregrino field in Brazil for USD 3.5 billion, focusing on the Bacalhau field start-up expected later in 2025 [15] - A long-term gas sales agreement was signed with Centrica for 55 TWh of natural gas per year over ten years, emphasizing the importance of gas supplies from the Norwegian continental shelf [14] Capital Distribution - An ordinary cash dividend of USD 0.37 per share was declared, with an expected total capital distribution of USD 9 billion for 2025, including a share buy-back program of up to USD 5 billion [17][18] - The third tranche of the share buy-back program, valued at up to USD 1.265 billion, is set to commence on July 24, 2025 [18]